Screening for benfluorex and its major urinary metabolites in routine doping controls

Analytical and Bioanalytical Chemistry

Volumn 401, Issue 2, 2011, Pages 543-551

  Thevis, Mario ^a   Sigmund, Gerd ^a   Gougoulidis, Vassilios ^a   Beuck, Simon ^a   Schlörer, Nils ^b   Thomas, Andreas ^a   Kwiatkowska, Dorota ^c   Pokrywka, Andrzej ^c   Schänzer, Wilhelm ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Institute of Sport National Research Institute   (Poland)

Author keywords

Benfluorex; Doping; Mass spectrometry; Orbitrap; Sport; Stimulants

Indexed keywords

BENFLUOREX; CARBOHYDRATE METABOLISM; DIABETIC PATIENT; DOPING CONTROL; DRUG TESTING; GLUCURONIC ACIDS; ION SUPPRESSION; LC-ESI-MS/MS; LC-MS/MS; LIMITS OF DETECTION; LIQUID-LIQUID EXTRACTION; METABOLIC DISORDERS; ORBITRAP; SPORT; STIMULANTS; TANDEM MASS SPECTROMETRY; URINARY METABOLITES; URINE DILUTION; WORLD ANTI-DOPING AGENCY;

BIOMOLECULES; CARBOHYDRATES; ELECTROSPRAY IONIZATION; GAS CHROMATOGRAPHY; GLUCOSE; IONIZATION OF GASES; LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; METABOLITES; PATIENT TREATMENT; SOLVENT EXTRACTION;

METABOLISM;

BENFLUOREX; DRUG DERIVATIVE; FENFLURAMINE; PERFORMANCE ENHANCING SUBSTANCE;

ARTICLE; CHEMISTRY; DOPING; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS FRAGMENTOGRAPHY; METABOLISM; METHODOLOGY; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; STANDARD; SUBSTANCE ABUSE; TANDEM MASS SPECTROMETRY; URINE;

CHROMATOGRAPHY, LIQUID; DOPING IN SPORTS; FENFLURAMINE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MIDDLE AGED; PERFORMANCE-ENHANCING SUBSTANCES; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY;

EID: 79960558448     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-010-4455-4     Document Type: Article

References (29)

1. Boulogene LB, Hugon P, and Le Douarec J-C (1971) in United States Patent Office, Science Union et Cie Societe Francaise de Recherche Medicale Suresnes, United States
2. Sittig M (1988) Pharmaceutical manufacturing encyclopedia. Noyes, New Jersey, p 140
3. Brindley DN (1993) "Mechanisms for the effects of benfluorex on the obese-diabetic-dyslipidemic syndrome", Diabetes Metab Rev 9 Suppl 1, 51S
4. K Boutet I Frachon Y Jobic C Gut-Gobert C Leroyer D Carlhant-Kowalski O Sitbon G Simonneau M Humbert 2009 Fenfluramine-like cardiovascular side-effects of benfluorex Eur Respir J 33 684 10.1183/09031936.00086308 1:STN:280: DC%2BD1M7ns1Khtg%3D%3D
5. P Noize M Sauer P Bruneval M Moreau A Pathak H Bagheri JL Montastruc 2006 Valvular heart disease in a patient taking benfluorex Fundam Clin Pharmacol 20 577 10.1111/j.1472-8206.2006.00441.x 1:CAS:528:DC%2BD2sXltlU%3D (Pubitemid 44762174)
6. EMEA (2009) European Union, London
7. TAS-CAS (2009) Tribunal Arbitral du Sport-Court of Arbitration for Sport, Lausanne
8. World Anti-Doping Agency (2010) "The 2010 Prohibited List", http://www.wada-ama.org/Documents/World-Anti-Doping-Program/WADP-Prohibited- list/WADA-Prohibited-List-2010-EN.pdf, 14-01-2010
9. M Thevis T Kuuranne H Geyer W Schänzer 2009 Annual banned-substance review: the Prohibited List 2008-analytical approaches in human sports drug testing Drug Test Anal 1 4 10.1002/dta.9 1:CAS:528:DC%2BD1MXkvFGmtLY%3D
10. M Thevis T Kuuranne H Geyer W Schänzer 2010 Annual banned-substance review: analytical approaches in human sports drug testing Drug Test Anal 2 149 10.1002/dta.128 1:CAS:528:DC%2BC3cXkt12ltbg%3D
11. AH Beckett EV Shenoy LG Brookes 1971 Determination of N-(2-benzoyloxyethyl)-norfenfluramine (JP 992) and its metabolites in urine J Pharm Pharmacol 23 950 10.1111/j.2042-7158.1971.tb09899.x 1:CAS:528: DyaE38XpsVCjsQ%3D%3D
12. AH Beckett EV Shenoy LG Brookes 1972 The absorption, metabolism and elimination of (plus minus)-N-(2-benzoyloxyethyl)norfenfluramine (JP992) in man J Pharm Pharmacol 24 281 10.1111/j.2042-7158.1972.tb08987.x 1:CAS:528: DyaE38Xkt1yksbk%3D
13. T Orsiere M Chauvet M Dell'Amico H Lafont M Bourdeaux 1995 In vitro influence of benfluorex and its main metabolites on rat liver microsomal membrane properties Chem Biol Interact 97 297 10.1016/0009-2797(95)03624-U 1:CAS:528:DyaK2MXnsFWgsbg%3D
14. Nolteernsting E, Opfermann G, and Donike M (1996) In recent advances in doping analysis Donike M, Geyer H, Gotzmann A, and Mareck-Engelke U (eds.), Sport & Buch Strauss, Cologne Vol. 3:pp. 369
15. M Donike L Jaenicke D Stratmann W Hollmann 1970 Gas chromatographic detection of nitrogen-containing drugs in aqueous solutions by means of the nitrogen detector J Chromatogr 52 237 10.1016/S0021-9673(01)96571-9 1:CAS:528:DyaE3MXhtVajsQ%3D%3D
16. M Donike 1970 Temperature programmed gas chromatographic analysis of nitrogen-containing drugs: the reproducibility of retention times (I) Chromatographia 3 422 10.1007/BF02279446 1:CAS:528:DyaE3MXhsFOnsw%3D%3D
17. Kromidas A (1999) Validierung in der Analytik. Wiley, Weinheim
18. R Dams MA Huestis WE Lambert CM Murphy 2003 Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid J Am Soc Mass Spectrom 14 1290 10.1016/S1044-0305(03) 00574-9 1:CAS:528:DC%2BD3sXosVWqsbs%3D (Pubitemid 37330133)
19. BK Matuszewski ML Constanzer CM Chavez-Eng 2003 Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS Anal Chem 75 3019 10.1021/ac020361s 1:CAS:528:DC%2BD3sXltV2jsL8%3D (Pubitemid 36830428)
20. M Thevis G Sigmund H Geyer W Schänzer 2010 Stimulants and doping in sport Endocrinol Metab Clin North Am 39 89 10.1016/j.ecl.2009.10.011 1:CAS:528:DC%2BC3cXjtFWhu78%3D
21. P Hemmersbach R de la Torre 1996 Stimulants, narcotics and β-blockers: 25 years of development in analytical techniques for doping control J Chromatogr B 687 221 10.1016/S0378-4347(96)00276-9 1:CAS:528:DyaK2sXntFWhuw%3D%3D (Pubitemid 27008321)
22. World Anti-Doping Agency (2008) "Minimum required performance levels for detection of prohibited substances", http://www.wada-ama.org/ rtecontent/document/MINIMUM-REQUIRED-PERFORMANCE-LEVELS-TD-v1-0-January-2009. pdf, 24-11-2008
23. Beckett AH, and Brookes LG (1967) "The absorption and urinary excretion in man of fenfluramine and its main metabolite", J Pharm Pharmacol 19: Suppl 42S
24. R Brownsill D Wallace A Taylor B Campbell 1991 Study of human urinary metabolism of fenfluramine using gas chromatography-mass spectrometry J Chromatogr 562 267 10.1016/0378-4347(91)80584-Y 1:CAS:528:DyaK3MXhsFKmtrg%3D
25. NC Marchant MA Breen D Wallace S Bass AR Taylor RM Ings DB Campbell J Williams 1992 Comparative biodisposition and metabolism of 14C-(+/-)- fenfluramine in mouse, rat, dog and man Xenobiotica 22 1251 10.3109/ 00498259209053154 1:CAS:528:DyaK3sXntlSluw%3D%3D
26. S Hammerum T Henriksen 2000 The rearrangement and simple cleavage of metastable octanamine radical cations Int J Mass Spectrom 199 79 10.1016/S1387-3806(00)00166-4 1:CAS:528:DC%2BD3cXltlSnt7Y%3D
27. S Hammerum CB Nielsen 2005 Intramolecular hydrogen bonding and hydrogen atom abstraction in gas-phase aliphatic amine radical cations J Phys Chem A 109 12046 10.1021/jp0550614 1:CAS:528:DC%2BD2MXht1ert7bK (Pubitemid 43063658)
28. S Hammerum K Norrman TI Solling PE Andersen LB Jensen T Vulpius 2005 Competing simple cleavage reactions: the elimination of alkyl radicals from amine radical cations J Am Chem Soc 127 6466 10.1021/ja043481l 1:CAS:528:DC%2BD2MXivFWrs7c%3D (Pubitemid 40627769)
29. RS Gohlke FW McLafferty 1962 Mass spectrometric analysis-aliphatic amines Anal Chem 34 1281 10.1021/ac60190a025 1:CAS:528:DyaF38Xksl2gt78%3D